查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1827938

兽用疫苗市场（依产品类型、动物类型、给药途径、疾病类型和分销管道划分）－2025-2032 年全球预测

Veterinary Vaccines Market by Product Type, Animal Type, Route Of Administration, Disease Type, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，兽用疫苗市场将成长至 241.5 亿美元，复合年增长率为 6.93%。

主要市场统计数据
基准年2024年 141.3亿美元
预计2025年 150.5亿美元
预测年份：2032年 241.5亿美元
复合年增长率（%） 6.93%

对动物疫苗现状、主要需求驱动因素、技术变革和相关人员的策略重点进行引人注目且全面的介绍

动物疫苗处于生物技术、动物福利和全球贸易动态的交汇点，其相关人员涵盖从研究机构到第一线兽医诊所的各个领域。本导论探讨了推动近期决策的核心主题，包括抗原设计和递送的科学创新、跨动物物种的疾病负担变化，以及依赖低温运输的生技药品的运作现状。本书以科学和商业性观点观点基础，为读者提供将实验室进展转化为临床成果和供应链执行的实用指导。

此外，引言部分概述了影响项目可行性和应用的关键因素，包括不断变化的免疫抗原性和安全性监管预期、伴侣动物和牲畜干预措施的经济性，以及分销网络在确保及时获取方面的作用。引言部分着重于实践见解而非抽象的趋势，并阐述了后续分析如何为研发、生产和商业团队的策略选择提供参考。

快速的技术创新、不断变化的动物保健模式、不断发展的监管环境以及新的商业模式如何重塑动物疫苗格局和价值链

兽用疫苗领域正在经历变革时期。分子生物学和载体工程的发展正在加速下一代平台的开发，包括次单元、重组和病毒载体方法，从而扩展了控制复杂病毒和寄生虫疾病的套件。同时，佐剂科学和製剂技术的进步使得製剂更加稳定，并减少了剂量。

同时，监管机构正在调整框架，以应对优先动物健康威胁的新模式和快速途径。这种监管变革既带来了机会，也带来了复杂性。某些化合物的快速审批流程与人们对上市后监测和批次放行数据的更高期望相平衡。在商业性，数位化兽医服务和线上分销管道正在再形成疫苗到达最终用户的方式，而远端医疗和电子商务正在改变伴侣动物疫苗的需求模式，并创造替代的市场途径。最后，对「同一健康」的日益观点正在使公共和私营部门的优先事项围绕着降低通用感染疾病风险进行协调。

评估 2025 年美国关税对进口、供应连续性、定价权和下游兽医服务的累积营运、成本和贸易影响

2025年实施的贸易措施和关税调整为兽用疫苗生产所用生技药品和辅助材料的全球供应链带来了新的摩擦。这些措施改变了以往以较低关税跨境运输的进口投入的计算方式，尤其是试剂、特殊黏合剂、一次性组件和成品。为此，製造商和经销商重新评估了筹资策略，加快了供应商资格认证计划，并考虑将关键供应线区域化，以降低受贸易相关成本波动影响的风险。

在营运方面，关税凸显了本地製造能力和仓储弹性的重要性。拥有现有区域生产基地的公司能够更有效地降低风险，而依赖远距进口的公司则面临更长的前置作业时间时间和更高的到岸成本。政策环境也促使合约重新谈判，并更多地使用外汇和采购对冲策略。对于临床和商业团队而言，实际结果是，他们重新将产品系列放在优先考虑能够保持供应可靠性和成本可预测性的地区，同时探索合作伙伴关係和许可，以实现针对特定区域的灌装和分销，从而在不断变化的贸易体制中保持市场进入。

深入的细分洞察揭示了产品类型、动物类别、给药途径、疾病目标和分销管道如何转化为临床应用和商业策略

细緻入微地了解市场区隔对于使产品策略与临床需求和商业性可行性保持一致至关重要。产品类型包括灭活疫苗、减毒活病毒疫苗、次单元疫苗、重组疫苗以及病毒载体疫苗，每种疫苗的开发时间表、安全性和低温运输依赖性各不相同，这些都会影响市场部署选择。伴侣动物市场主要集中在猫和狗，强调便利性、安全性和饲主主导的购买行为。同时，在畜牧业中，规模效益和监管监督决定了采用动态，优先考虑牛、家禽、羊和猪的群体级疾病控制。

给药途径进一步区分，口服、肠胃外和局部製剂在给药的简易性、免疫反应品质和製剂复杂性之间提供各种权衡。细菌、感染疾病、寄生虫和病毒感染疾病的疫苗需要不同的设计和给药策略。细菌感染疾病包括大肠桿菌病、结肠感染疾病症候群、钩端螺旋体病和巴氏桿菌症，每种感染都需要优化目标抗原，通常还需要佐剂。寄生虫感染疾病既针对体外寄生虫也针对体内寄生虫，需要在疫苗保护与环境和管理控制之间取得平衡。病毒疫苗针对的病毒种类繁多，从禽流感病毒到牛病毒性腹泻病毒、口蹄疫病毒、新城疫病毒、猪繁殖与呼吸综合症病毒和狂犬病毒，每种病毒都有其自身的免疫学挑战和监管考虑。最后，分销管道动态——透过线上药局、零售药局和兽医诊所——影响着商业性执行。诊所直接分销有利于医生的影响力和低温运输管理，零售药局为消费者提供便利，而线上药局则开闢了新的购买途径，需要数位化物流和疫苗产品的信任建立。

区域情报重点介绍美洲、欧洲、中东和非洲地区以及亚太地区的不同需求驱动因素、监管细节、製造地和分销挑战

地理动态显着影响疫苗研发重点、监管策略和分销方式。美洲地区拥有强大的兽医基础设施、较高的伴侣动物收养率以及​​成熟的商业管道，支持高级产品和数位化分销模式的快速普及。该地区的生产商正在利用先进的低温运输物流来支援复杂的生技药品，同时越来越重视生命週期数据和上市后安全监测。

在欧洲、中东和非洲，监管协调工作与生产能力和购买力的巨大差异并存。该地区需要灵活的策略来应对某些市场严格的监管预期，以及其他市场产能增加或成本驱动的模式。同时，亚太地区拥有大规模畜牧生产系统、新兴製造地和日益壮大的伴侣动物养殖业，这不仅创造了大规模生产的机会，也带来了对可扩展、本地化客製化供应解决方案的需求。在所有地区，本地监管途径、进口限制和分销基础设施仍然是新型动物疫苗产品商业规划和部署的关键因素。

分析领先开发商、生技药品製造商、委託製造、经销商和服务供应商之间的竞争和合作行为，塑造策略定位和创新

兽用疫苗领域的竞争态势由拥有深厚研发实力、生产规模和分销网络的公司所塑造。其中一条策略轴线是将公司划分为两类：一类公司大力投资专有平台技术和产品线多元化，另一类公司则专注于利基市场或合约服务，例如填充和低温运输物流。伙伴关係和授权协议是弥补能力差距的常用机制。专注于研究的机构经常与大型製造商合作，以加速商业化进程，而区域经销商和临床网路则提供市场渗透能力。

另一个重要趋势是製造外包和专业生技药品服务提供者的角色日益增强，这使得规模较小的创新企业无需大量资本投入即可扩大规模。次单元和病毒载体尤其需要专业的製程专业知识。从商业策略角度来看，将临床证据产生与务实的分销模式（确保为最终用户提供合适的包装、标籤和低温运输完整性）相结合的公司往往能获得更广泛的从业者认可和采用。最后，随着业界寻求提高整个价值链的效率，解决低温运输标准化、监管协调和上市后监管等跨领域问题的合作措施变得越来越重要。

为产业领导者提供具影响力的策略建议，以加速疫苗创新、增强供应弹性、优化市场进入并改善跨通路的商业性执行。

领导者应优先考虑一系列切实有效、卓有成效的措施，以应对当前环境并抓住机会。首先，投资平台多功能性和模组化製造能力，以快速适应不同的抗原类型和剂型。其次，加强供应商多元化和资格确认计划，以降低关税带来的采购风险。这包括与合格的契约製造和本地灌装合作伙伴建立关係，以便在贸易政策变化时保持连续性。

第三，我们将儘早调整监管策略，使其与目标市场需求一致，并规划强而有力的上市后监管，以满足不断变化的安全预期。透过平行磋商与监管机构合作，可以缩短创新模式的核准途径。第四，我们将透过协调伴侣动物和牲畜管道的分销方式、在适当情况下整合数位销售和远端医疗，以及确保为兽医和辅助专业人员提供实地培训，来改善控制和合规性，优化商业模式。最后，我们将开展倡议，增强相关人员的信心，并透过提高低温运输韧性和共用不利事件监测数据平台，支援下一代疫苗的快速部署。

一种强大的混合调查方法，结合主要相关人员调查、二手文献综合和严格的数据三角测量，以确保分析的有效性和可重复性。

本研究的基础研究采用了混合方法，旨在兼顾深度和相关性。主要研究包括与科学研究领导者、监管专家、生产高管和分销合作伙伴进行结构化访谈，以突出实际限制和未来重点。这些定性资讯为专题研究的重点提供了信息，并指南了有针对性的后续研究，以明确技术依赖性和商业性考虑。除了主要资讯外，我们还广泛整合了同行评审文献、监管指南文件和行业白皮书，为平台和疾病特异性分析提供了技术基础。

我们运用资料三角检定来协调资讯来源之间的差异并检验推论的结论。在可能的情况下，技术声明由多个独立相关人员进行佐证，以减少偏差。调查方法强调预测假设的透明度和记录的分析界限，包括排除推测性预测和专有财务指标。此外，我们反覆进行同侪审查，以确保临床、生产和商业性解读的稳健性并与现行实践保持一致。

简要概括策略要点、突出挑战和近期优先事项，供高阶决策者在应对不断发展的动物疫苗生态系统时采取行动

本分析综合了技术进步、法规演变、市场区隔现状、区域动态以及贸易政策变化对兽用疫苗产业的策略影响。关键要点包括：平衡技术创新与营运韧性的必要性、区域製造和分销敏捷性的策略价值，以及基于细分市场的产品策略的重要性，该策略反映了伴侣动物市场和畜牧市场之间的差异。总而言之，这些见解表明，在平台、供应链多元化和监管参与方面的战术性投资，能够在市场进入和临床应用方面获得丰厚回报。

展望未来，决策者不应将疫苗研发视为线性产品计划，而应将其视为一个整合科学、製造、监管和现场执行的生态系统挑战。这样做将使研发投资与更切合实际的落地路径保持一致，减少外部衝击的影响，并加速科学进步转化为可衡量的动物健康成果。因此，这个结论强调了将技术进步转化为永续商业性优势的综合、跨职能方法的必要性。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 越来越多地使用基于mRNA的兽用疫苗来对抗新出现的牲畜疾病
  • 将人工智慧驱动的诊断技术整合到疫苗开发平臺中，以加快核准时间
  • 扩大多种病原体的联合疫苗，以减少家禽的接种频率
  • 开发耐热疫苗製剂以提高偏远地区的低温运输耐受性
  • 针对特定族群健康管理和疫情控制的自体疫苗需求不断增加
  • 增加对奈米颗粒疫苗佐剂的投资，以增强牲畜的免疫反应

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第 8 章：动物疫苗市场（依产品类型）

  • 灭活疫苗
  • 减毒活疫苗
  • 次单位疫苗和重组疫苗
  • 病毒载体疫苗

9. 动物疫苗市场（依动物类型）

  • 伴侣动物
    • 猫
    • 狗
  • 家畜
    • 牛
    • 家禽
    • 羊
    • 猪

第 10 章：按管理途径分類的动物疫苗市场

  • 口服
  • 肠外
  • 话题

第 11 章：动物疫苗市场（依疾病类型）

  • 细菌感染疾病
    • 梭菌
    • 大肠桿菌
    • 钩端螺旋体病
    • 巴氏桿菌
  • 霉菌感染疾病
  • 寄生虫感染疾病
    • 体外寄生虫
    • 体内寄生虫
  • 病毒感染
    • 禽流感病毒
    • 牛病毒性腹泻病毒（BVDV）
    • 口蹄疫病毒（FMDV）
    • 新城疫病毒
    • 猪繁殖与呼吸综合症病毒（PRRSV）
    • 狂犬病毒

第 12 章：动物疫苗市场（依通路）

  • 网路药局
  • 零售药局
  • 兽医诊所

第 13 章：兽用疫苗市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 14 章：动物疫苗市场（按类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章。按国家/地区分類的动物疫苗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Arko Corp.
    • Bimeda Biologicals Inc
    • Biogenesis Bago SA
    • Boehringer Ingelheim International GmbH
    • Ceva Sante Animale
    • Dechra Pharmaceuticals PLC
    • Elanco Animal Health Incorporated
    • Endovac Animal Health
    • Hester Biosciences Limited
    • Hipra SA
    • Huvepharma, Inc.
    • Indian Immunologicals Ltd.
    • Kemin Industries, Inc.
    • Merck & Co., Inc.
    • Neogen Corporation
    • Pfizer, Inc.
    • Phibro Animal Health Corporation
    • SAN Group Biotech Germany GmbH
    • Seppic by Air Liquide Healthcare
    • SK Bioscience
    • Vaxxinova
    • Virbac SA
    • Zoetis Inc.
Product Code: MRR-4316E4E89380

The Veterinary Vaccines Market is projected to grow by USD 24.15 billion at a CAGR of 6.93% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 14.13 billion
Estimated Year [2025] USD 15.05 billion
Forecast Year [2032] USD 24.15 billion
CAGR (%) 6.93%

A compelling, comprehensive introduction that frames the current state of veterinary vaccines, key demand drivers, technological inflections, and strategic priorities for stakeholders globally

The veterinary vaccines domain sits at the intersection of biotechnology, animal welfare, and global trade dynamics, with stakeholders ranging from research laboratories to frontline veterinary practices. This introduction frames the core themes that drive near-term decision-making: scientific innovation in antigen design and delivery, shifting disease burdens across species, and the operational realities of cold-chain dependent biologics. By grounding the narrative in both scientific and commercial perspectives, readers gain a practical orientation that links laboratory advances to clinic-level outcomes and supply-chain execution.

In addition, the introduction outlines the primary levers that influence program viability and adoption. These include evolving regulatory expectations for immunogenicity and safety, the economics of companion animal versus livestock interventions, and the role of distribution networks in ensuring timely access. Taken together, the early section establishes the analytical lens used throughout the study, emphasizing actionable insights over abstract trends and setting expectations for how subsequent analysis will translate into strategic choices for R&D, manufacturing, and commercial teams.

How rapid technological innovation, shifting animal health paradigms, evolving regulatory frameworks, and new commercial models are together reshaping the veterinary vaccines landscape and value chains

The landscape of veterinary vaccines is undergoing a period of transformative change driven by multiple, interlocking forces. Advances in molecular biology and vector engineering have accelerated the development of next-generation platforms such as subunit, recombinant, and viral vector approaches, expanding the toolkit available to control complex viral and parasitic diseases. Concurrently, improvements in adjuvant science and formulation technologies are enabling more stable products with reduced dosing requirements, which in turn affect logistics, dosing regimens, and uptake among practitioners.

At the same time, regulatory authorities are adapting frameworks to accommodate novel modalities and expedited pathways for high-priority animal health threats. This regulatory evolution is producing both opportunities and complexities: faster pathways for certain constructs are balanced by heightened expectations for post-market surveillance and batch-release data. Commercially, digital veterinary services and online distribution channels are reshaping how vaccines reach end users, with telemedicine and e-commerce altering demand patterns for companion animal vaccines and creating alternate routes to market. Finally, growing emphasis on One Health perspectives is aligning public and private priorities around zoonotic risk mitigation, which increases collaboration across human and animal health domains and elevates investment in vaccines that reduce cross-species transmission.

Assessing the cumulative operational, cost and trade impacts of the United States tariffs enacted in 2025 on imports, supply continuity, pricing dynamics, and downstream veterinary services

The imposition of trade measures and tariff adjustments in 2025 introduced new friction into global supply chains for biologics and ancillary materials used in veterinary vaccine manufacture. These measures have changed the calculus for imported inputs, particularly reagents, specialty adhesives, single-use components, and finished-dose products that historically moved across borders with lower tariff exposure. In response, manufacturers and distributors have reassessed sourcing strategies, accelerated supplier qualification programs, and explored regionalization of critical supply lines to reduce vulnerability to trade-related cost volatility.

Operationally, the tariffs have amplified the importance of local manufacturing capacity and warehousing agility. Firms with pre-existing regional production hubs were able to mitigate exposure more effectively, whereas organizations reliant on long-haul imports faced longer lead times and higher landed costs. The policy environment has also encouraged contractual renegotiations and greater use of hedging strategies for currency and procurement. For clinical and commercial teams, the practical outcome has been a renewed focus on prioritizing product portfolios for geographies where supply reliability and cost predictability can be maintained, while exploring partnerships and licensing that allow for localized fill-finish and distribution to preserve market access under changing trade regimes.

Deep segmentation insights revealing how product types, animal categories, administration routes, disease targets, and distribution channels collectively inform clinical adoption and commercial strategies

A nuanced understanding of market segmentation is essential to align product strategy with clinical need and commercial feasibility. Based on product type, the domain includes Inactivated Vaccines, Live Attenuated Vaccines, Subunit & Recombinant Vaccines, and Viral Vector Vaccines, each presenting distinct development timelines, safety profiles, and cold-chain dependencies that influence go-to-market choices. When examined by animal type, the market divides between Companion Animals and Livestock Animals; companion animal work largely concentrates on Cats and Dogs with emphasis on convenience, safety and owner-driven purchasing behavior, while livestock efforts prioritize herd-level disease control across Cattle, Poultry, Sheep, and Swine with scale efficiencies and regulatory oversight shaping adoption dynamics.

Route of administration introduces further differentiation, with Oral, Parenteral, and Topical delivery pathways offering varying trade-offs between ease of administration, immune response quality, and formulation complexity. Disease-type considerations add another strategic layer: vaccines targeting Bacterial Infections, Fungal Infections, Parasitic Infections, and Viral Infections must be designed and communicated differently. Bacterial indications encompass Clostridial illness, E. coli syndromes, Leptospirosis, and Pasteurella, each requiring targeted antigens and often adjuvant optimization. Parasitic disease work addresses both Ectoparasites and Endoparasites, where vaccine-induced protection must be balanced against environmental and management controls. Viral vaccine targets range from Avian Influenza Virus to Bovine Viral Diarrhea Virus, Foot-and-Mouth Disease Virus, Newcastle Disease Virus, Porcine Reproductive & Respiratory Syndrome Virus, and Rabies Virus, each presenting unique immunological challenges and regulatory considerations. Finally, distribution channel dynamics across Online Pharmacies, Retail Pharmacies, and Veterinary Clinics shape commercial execution: direct clinic distribution favors practitioner influence and cold-chain stewardship, retail pharmacies offer consumer convenience, and online pharmacies create new purchasing pathways that require digital logistics and trust-building for vaccine products.

Region-focused intelligence highlighting differentiated demand drivers, regulatory nuances, manufacturing hubs, and distribution challenges across the Americas, EMEA, and Asia-Pacific regions

Geographic dynamics materially influence vaccine development priorities, regulatory strategy, and distribution approaches. In the Americas, strong veterinary infrastructure, high companion animal ownership rates, and established commercial channels favor rapid adoption of premium products and digital distribution models. Producers in this region increasingly emphasize lifecycle data and post-market safety monitoring while leveraging sophisticated cold-chain logistics to support complex biologics.

Across Europe, Middle East & Africa, regulatory harmonization efforts coexist with wide heterogeneity in manufacturing capacity and purchasing power. This region demands flexible strategies that accommodate stringent regulatory expectations in some markets alongside capacity-building and cost-sensitive models in others. Meanwhile, Asia-Pacific reflects a mix of large-scale livestock production systems, emergent manufacturing hubs, and rising companion animal ownership that together create both high-volume opportunities and the need for scalable, locally adapted supply solutions. Across all regions, local regulatory pathways, import controls, and distribution infrastructures remain decisive factors in the commercial planning and rollout of new veterinary vaccine products.

Competitive and collaborative behavior analysis among leading developers, biologics formulators, contract manufacturers, distributors, and service providers shaping strategic positioning and innovation

Competitive dynamics in the veterinary vaccines space are shaped by companies that combine R&D depth, manufacturing scale, and distribution reach. One strategic axis separates organizations that invest heavily in proprietary platform technologies and pipeline diversity from those that focus on niche indications or contract services such as fill-finish and cold-chain logistics. Partnerships and licensing agreements serve as common mechanisms to bridge capability gaps: research-focused entities frequently collaborate with large-scale manufacturers to expedite commercial access, while regional distributors and clinical networks provide market penetration capacity.

Another important trend is the increasing role of contract manufacturing and specialized biologics service providers that enable smaller innovators to scale without extensive capital investment. These arrangements influence time-to-market and create modular paths to commercialization, especially for subunit and viral vector constructs that demand specific process expertise. From a commercial strategy perspective, companies that align clinical evidence generation with pragmatic distribution models-ensuring appropriate packaging, labeling and cold-chain integrity for end users-tend to achieve better practitioner acceptance and uptake. Finally, collaborative initiatives that address cross-cutting challenges such as cold-chain standardization, regulatory harmonization, and post-market surveillance are becoming more prominent as the industry seeks efficiencies across the value chain.

High-impact strategic recommendations for industry leaders to accelerate vaccine innovation, strengthen supply resilience, optimize market access, and improve commercial execution across channels

Leaders should prioritize a set of pragmatic, high-impact measures to navigate the current environment and capture opportunity. First, invest in platform versatility and modular manufacturing capabilities that allow rapid reconfiguration for different antigen types and dosing formats; this reduces time-to-clinic and supports regional production strategies. Second, strengthen supplier diversification and qualification programs to mitigate tariff-driven sourcing risks, including building relationships with qualified contract manufacturers and local fill-finish partners to preserve continuity under shifting trade policies.

Third, align regulatory strategies early with target market requirements and plan for robust post-market surveillance to satisfy evolving safety expectations; engaging with regulators through parallel consultations can shorten approval pathways for innovative modalities. Fourth, optimize commercial models by tailoring distribution approaches for companion animal versus livestock channels, integrating digital sales and telemedicine where appropriate, and ensuring field-level training for veterinarians and paraprofessionals to improve administration and compliance. Lastly, pursue collaborative initiatives that advance cold-chain resilience and shared data platforms for adverse event monitoring, which will enhance stakeholder confidence and support more rapid adoption of next-generation vaccines.

Robust mixed-methods research methodology combining primary stakeholder engagement, secondary literature synthesis, and rigorous data triangulation to ensure analytical validity and reproducibility

The research underpinning this study follows a mixed-methods approach designed to balance depth and validity. Primary engagement included structured interviews with scientific leaders, regulatory specialists, manufacturing executives, and distribution partners to surface practical constraints and forward-looking priorities. These qualitative inputs informed thematic priorities and guided targeted follow-ups that clarified technical dependencies and commercial considerations. Alongside primary input, an extensive synthesis of peer-reviewed literature, regulatory guidance documents, and industry whitepapers provided the technical foundation for platform-specific and disease-targeted analysis.

Data triangulation was applied to reconcile differences across sources and to validate inferred conclusions. Where possible, technical assertions were corroborated by multiple independent stakeholders to reduce bias. The methodology emphasizes transparency in assumptions and documents analytical boundaries, including the exclusion of speculative forecasts or proprietary financial metrics. In addition, the study incorporated iterative reviews by subject matter experts to ensure that clinical, manufacturing, and commercial interpretations remain robust and aligned with current practice.

Concise synthesis of strategic takeaways, unresolved challenges, and near-term priorities that senior decision-makers should act on to navigate the evolving animal vaccine ecosystem

This analysis synthesizes the strategic implications of technological progress, regulatory evolution, segmentation realities, regional dynamics, and trade policy shifts for the veterinary vaccines sector. Key takeaways include the imperative to balance innovation with operational resilience, the strategic value of regional manufacturing and distribution agility, and the importance of segmentation-informed product strategies that reflect differences between companion animal and livestock markets. Collectively, these insights underscore that tactical investments in platforms, supply chain diversity, and regulatory engagement deliver outsized returns in market access and clinical uptake.

Looking ahead, decision-makers should treat vaccine development not as a linear product project but as an ecosystem challenge that integrates science, manufacturing, regulation, and field execution. By doing so, organizations can better align R&D investments to practical adoption pathways, reduce exposure to external shocks, and accelerate the translation of scientific advances into measurable animal health outcomes. The conclusion therefore reinforces the need for integrated, cross-functional approaches that convert technical advances into durable commercial advantage.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing use of mRNA-based veterinary vaccines to address emerging livestock diseases
  • 5.2. Integration of AI-driven diagnostics in vaccine development pipelines for faster approval times
  • 5.3. Expansion of combination vaccines targeting multiple pathogens to reduce dosing frequency in poultry
  • 5.4. Growth of thermostable vaccine formulations to improve cold chain resilience in remote regions
  • 5.5. Rising demand for autogenous vaccines tailored for specific herd health management and outbreak control
  • 5.6. Increased investment in nanoparticle vaccine adjuvants to enhance immune response in livestock species

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Veterinary Vaccines Market, by Product Type

  • 8.1. Inactivated Vaccines
  • 8.2. Live Attenuated Vaccines
  • 8.3. Subunit & Recombinant Vaccines
  • 8.4. Viral Vector Vaccines

9. Veterinary Vaccines Market, by Animal Type

  • 9.1. Companion Animals
    • 9.1.1. Cats
    • 9.1.2. Dogs
  • 9.2. Livestock Animals
    • 9.2.1. Cattle
    • 9.2.2. Poultry
    • 9.2.3. Sheep
    • 9.2.4. Swine

10. Veterinary Vaccines Market, by Route Of Administration

  • 10.1. Oral
  • 10.2. Parenteral
  • 10.3. Topical

11. Veterinary Vaccines Market, by Disease Type

  • 11.1. Bacterial Infections
    • 11.1.1. Clostridial
    • 11.1.2. E. Coli
    • 11.1.3. Leptospirosis
    • 11.1.4. Pasteurella
  • 11.2. Fungal Infections
  • 11.3. Parasitic Infections
    • 11.3.1. Ectoparasites
    • 11.3.2. Endoparasites
  • 11.4. Viral Infections
    • 11.4.1. Avian Influenza Virus
    • 11.4.2. Bovine Viral Diarrhea Virus (BVDV)
    • 11.4.3. Foot-and-Mouth Disease Virus (FMDV)
    • 11.4.4. Newcastle Disease Virus
    • 11.4.5. Porcine Reproductive & Respiratory Syndrome Virus (PRRSV)
    • 11.4.6. Rabies Virus

12. Veterinary Vaccines Market, by Distribution Channel

  • 12.1. Online Pharmacies
  • 12.2. Retail Pharmacies
  • 12.3. Veterinary Clinics

13. Veterinary Vaccines Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Veterinary Vaccines Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Veterinary Vaccines Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Arko Corp.
    • 16.3.2. Bimeda Biologicals Inc
    • 16.3.3. Biogenesis Bago S.A.
    • 16.3.4. Boehringer Ingelheim International GmbH
    • 16.3.5. Ceva Sante Animale
    • 16.3.6. Dechra Pharmaceuticals PLC
    • 16.3.7. Elanco Animal Health Incorporated
    • 16.3.8. Endovac Animal Health
    • 16.3.9. Hester Biosciences Limited
    • 16.3.10. Hipra S.A.
    • 16.3.11. Huvepharma, Inc.
    • 16.3.12. Indian Immunologicals Ltd.
    • 16.3.13. Kemin Industries, Inc.
    • 16.3.14. Merck & Co., Inc.
    • 16.3.15. Neogen Corporation
    • 16.3.16. Pfizer, Inc.
    • 16.3.17. Phibro Animal Health Corporation
    • 16.3.18. SAN Group Biotech Germany GmbH
    • 16.3.19. Seppic by Air Liquide Healthcare
    • 16.3.20. SK Bioscience
    • 16.3.21. Vaxxinova
    • 16.3.22. Virbac S.A.
    • 16.3.23. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VETERINARY VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VETERINARY VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS VETERINARY VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL VETERINARY VACCINES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. VETERINARY VACCINES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. VETERINARY VACCINES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. VETERINARY VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL VETERINARY VACCINES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL VETERINARY VACCINES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL VETERINARY VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL VETERINARY VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL VETERINARY VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL VETERINARY VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL VETERINARY VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL VETERINARY VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SUBUNIT & RECOMBINANT VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SUBUNIT & RECOMBINANT VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SUBUNIT & RECOMBINANT VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SUBUNIT & RECOMBINANT VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SUBUNIT & RECOMBINANT VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SUBUNIT & RECOMBINANT VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL VECTOR VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL VECTOR VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL VECTOR VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL VECTOR VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL VECTOR VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL VECTOR VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CATS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CATS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CATS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CATS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CATS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CATS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DOGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DOGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DOGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DOGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DOGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CATTLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CATTLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CATTLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CATTLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CATTLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL VETERINARY VACCINES MARKET SIZE, BY POULTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL VETERINARY VACCINES MARKET SIZE, BY POULTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL VETERINARY VACCINES MARKET SIZE, BY POULTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL VETERINARY VACCINES MARKET SIZE, BY POULTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL VETERINARY VACCINES MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL VETERINARY VACCINES MARKET SIZE, BY POULTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SHEEP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SHEEP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SHEEP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SHEEP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SHEEP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SHEEP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SWINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SWINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SWINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SWINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SWINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL VETERINARY VACCINES MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL VETERINARY VACCINES MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL VETERINARY VACCINES MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL VETERINARY VACCINES MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL VETERINARY VACCINES MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL VETERINARY VACCINES MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CLOSTRIDIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CLOSTRIDIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CLOSTRIDIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CLOSTRIDIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CLOSTRIDIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CLOSTRIDIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL VETERINARY VACCINES MARKET SIZE, BY E. COLI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL VETERINARY VACCINES MARKET SIZE, BY E. COLI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL VETERINARY VACCINES MARKET SIZE, BY E. COLI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL VETERINARY VACCINES MARKET SIZE, BY E. COLI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL VETERINARY VACCINES MARKET SIZE, BY E. COLI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL VETERINARY VACCINES MARKET SIZE, BY E. COLI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LEPTOSPIROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LEPTOSPIROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LEPTOSPIROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LEPTOSPIROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LEPTOSPIROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LEPTOSPIROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PASTEURELLA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PASTEURELLA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PASTEURELLA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PASTEURELLA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PASTEURELLA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PASTEURELLA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL VETERINARY VACCINES MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL VETERINARY VACCINES MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL VETERINARY VACCINES MARKET SIZE, BY FUNGAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL VETERINARY VACCINES MARKET SIZE, BY FUNGAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL VETERINARY VACCINES MARKET SIZE, BY FUNGAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL VETERINARY VACCINES MARKET SIZE, BY FUNGAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ECTOPARASITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ECTOPARASITES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ECTOPARASITES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ECTOPARASITES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ECTOPARASITES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ECTOPARASITES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ENDOPARASITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ENDOPARASITES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ENDOPARASITES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ENDOPARASITES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ENDOPARASITES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ENDOPARASITES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL VETERINARY VACCINES MARKET SIZE, BY AVIAN INFLUENZA VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL VETERINARY VACCINES MARKET SIZE, BY AVIAN INFLUENZA VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL VETERINARY VACCINES MARKET SIZE, BY AVIAN INFLUENZA VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL VETERINARY VACCINES MARKET SIZE, BY AVIAN INFLUENZA VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL VETERINARY VACCINES MARKET SIZE, BY AVIAN INFLUENZA VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL VETERINARY VACCINES MARKET SIZE, BY AVIAN INFLUENZA VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BOVINE VIRAL DIARRHEA VIRUS (BVDV), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BOVINE VIRAL DIARRHEA VIRUS (BVDV), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BOVINE VIRAL DIARRHEA VIRUS (BVDV), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BOVINE VIRAL DIARRHEA VIRUS (BVDV), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BOVINE VIRAL DIARRHEA VIRUS (BVDV), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BOVINE VIRAL DIARRHEA VIRUS (BVDV), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL VETERINARY VACCINES MARKET SIZE, BY FOOT-AND-MOUTH DISEASE VIRUS (FMDV), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL VETERINARY VACCINES MARKET SIZE, BY FOOT-AND-MOUTH DISEASE VIRUS (FMDV), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL VETERINARY VACCINES MARKET SIZE, BY FOOT-AND-MOUTH DISEASE VIRUS (FMDV), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL VETERINARY VACCINES MARKET SIZE, BY FOOT-AND-MOUTH DISEASE VIRUS (FMDV), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL VETERINARY VACCINES MARKET SIZE, BY FOOT-AND-MOUTH DISEASE VIRUS (FMDV), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL VETERINARY VACCINES MARKET SIZE, BY FOOT-AND-MOUTH DISEASE VIRUS (FMDV), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL VETERINARY VACCINES MARKET SIZE, BY NEWCASTLE DISEASE VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL VETERINARY VACCINES MARKET SIZE, BY NEWCASTLE DISEASE VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL VETERINARY VACCINES MARKET SIZE, BY NEWCASTLE DISEASE VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL VETERINARY VACCINES MARKET SIZE, BY NEWCASTLE DISEASE VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL VETERINARY VACCINES MARKET SIZE, BY NEWCASTLE DISEASE VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL VETERINARY VACCINES MARKET SIZE, BY NEWCASTLE DISEASE VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE & RESPIRATORY SYNDROME VIRUS (PRRSV), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE & RESPIRATORY SYNDROME VIRUS (PRRSV), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE & RESPIRATORY SYNDROME VIRUS (PRRSV), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE & RESPIRATORY SYNDROME VIRUS (PRRSV), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE & RESPIRATORY SYNDROME VIRUS (PRRSV), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE & RESPIRATORY SYNDROME VIRUS (PRRSV), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL VETERINARY VACCINES MARKET SIZE, BY RABIES VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL VETERINARY VACCINES MARKET SIZE, BY RABIES VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL VETERINARY VACCINES MARKET SIZE, BY RABIES VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL VETERINARY VACCINES MARKET SIZE, BY RABIES VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL VETERINARY VACCINES MARKET SIZE, BY RABIES VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL VETERINARY VACCINES MARKET SIZE, BY RABIES VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL VETERINARY VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL VETERINARY VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL VETERINARY VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL VETERINARY VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL VETERINARY VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL VETERINARY VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL VETERINARY VACCINES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL VETERINARY VACCINES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS VETERINARY VACCINES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS VETERINARY VACCINES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 292. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 296. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPE, MIDDLE EAST & AFR